Found: 2564
Select item for more details and to access through your institution.
Dysphasia: metastatic prostate cancer to the leptomeninges: a case report.
- Published in:
- 2024
- By:
- Publication type:
- Case Study
The Current Status of Comprehensive Genomic Profiling in the Management of Metastatic Castration-Resistant Prostate Cancer: A Study from a Cooperative Hospital for Cancer Genomic Medicine in Japan.
- Published in:
- Journal of Nippon Medical School, 2024, v. 91, n. 5, p. 472, doi. 10.1272/jnms.JNMS.2024_91-512
- By:
- Publication type:
- Article
Analysis of Molecular Imaging Biomarkers Derived from [ 18 F]FDG PET/CT in mCRPC: Whole-Body Total Lesion Glycolysis (TLG) Predicts Overall Survival in Patients Undergoing [ 225 Ac]Ac-PSMA-617-Augmented [ 177 Lu]Lu-PSMA-617 Radioligand Therapy.
- Published in:
- Cancers, 2024, v. 16, n. 20, p. 3532, doi. 10.3390/cancers16203532
- By:
- Publication type:
- Article
Assessment of Different Castration Resistance Definitions and Staging Modalities in Metastatic Castration-Resistant Prostate Cancer.
- Published in:
- Cancers, 2024, v. 16, n. 20, p. 3506, doi. 10.3390/cancers16203506
- By:
- Publication type:
- Article
Effect of N-methyl deuteration on pharmacokinetics and pharmacodynamics of enzalutamide.
- Published in:
- Journal of Labelled Compounds & Radiopharmaceuticals, 2017, v. 60, n. 9, p. 401, doi. 10.1002/jlcr.3516
- By:
- Publication type:
- Article
Targeting the signalling pathways regulated by deubiquitinases for prostate cancer therapeutics.
- Published in:
- Cell Biochemistry & Function, 2019, v. 37, n. 5, p. 304, doi. 10.1002/cbf.3401
- By:
- Publication type:
- Article
Primary mismatch repair–deficient prostate cancer can be identified prospectively in prostate biopsies and radical prostatectomies.
- Published in:
- Virchows Archiv: European Journal of Pathology, 2024, v. 484, n. 5, p. 869, doi. 10.1007/s00428-024-03789-6
- By:
- Publication type:
- Article
GUEST EDITORIAL: Theranostics in breast cancer—a vision.
- Published in:
- 2023
- By:
- Publication type:
- Editorial
Advances in bio-immunotherapy for castration-resistant prostate cancer.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 14, p. 13451, doi. 10.1007/s00432-023-05152-9
- By:
- Publication type:
- Article
Salvage prostate bed plus elective pelvic node radiation without androgen deprivation therapy.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 14, p. 13231, doi. 10.1007/s00432-023-05085-3
- By:
- Publication type:
- Article
Eprinomectin: a derivative of ivermectin suppresses growth and metastatic phenotypes of prostate cancer cells by targeting the β-catenin signaling pathway.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 11, p. 9085, doi. 10.1007/s00432-023-04829-5
- By:
- Publication type:
- Article
Neuroendocrine differentiation predicts the therapeutic efficacy of abiraterone and docetaxel as first-line therapy in metastatic castration-resistant prostate cancer.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 10, p. 7247, doi. 10.1007/s00432-023-04639-9
- By:
- Publication type:
- Article
Castration-resistant prostate cancer cells are dependent on the high activity of CDK7.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 8, p. 5255, doi. 10.1007/s00432-022-04475-3
- By:
- Publication type:
- Article
Adjuvant radiotherapy in patients with node-positive prostate cancer after radical prostatectomy.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 8, p. 4925, doi. 10.1007/s00432-022-04409-z
- By:
- Publication type:
- Article
Low TLR and PSMA-TV predict biochemical response to abiraterone acetate in metastatic prostate cancer patients developing castration resistance after chemohormonal therapy at hormone-sensitive stage.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 8, p. 5071, doi. 10.1007/s00432-022-04438-8
- By:
- Publication type:
- Article
Extracellular vesicles from biological fluids as potential markers in castration resistant prostate cancer.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 8, p. 4701, doi. 10.1007/s00432-022-04391-6
- By:
- Publication type:
- Article
Systemic inflammatory biomarkers as predictive and prognostic factors in men with metastatic castration-refractory prostate cancer treated with docetaxel therapy: a comprehensive analysis in a German real-world cohort.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 7, p. 3371, doi. 10.1007/s00432-022-04220-w
- By:
- Publication type:
- Article
Efficacy and safety of sintilimab plus docetaxel in patients with previously treated advanced non-small cell lung cancer: a prospective, single-arm, phase II study in China.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 4, p. 1443, doi. 10.1007/s00432-022-04023-z
- By:
- Publication type:
- Article
Acquired resistance to irradiation or docetaxel is not associated with cross-resistance to cisplatin in prostate cancer cell lines.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2022, v. 148, n. 6, p. 1313, doi. 10.1007/s00432-022-03914-5
- By:
- Publication type:
- Article
Biopsy-detected Gleason grade 5 tumor is an additional prognostic factor in metastatic hormone-sensitive prostate cancer.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2022, v. 148, n. 3, p. 727, doi. 10.1007/s00432-021-03642-2
- By:
- Publication type:
- Article
Antihormone treatment differentially regulates PSA secretion, PSMA expression and 68Ga–PSMA uptake in LNCaP cells.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2021, v. 147, n. 6, p. 1733, doi. 10.1007/s00432-021-03583-w
- By:
- Publication type:
- Article
A clinician's guide for developing a prediction model: a case study using real-world data of patients with castration-resistant prostate cancer.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2020, v. 146, n. 8, p. 2067, doi. 10.1007/s00432-020-03286-8
- By:
- Publication type:
- Article
Predictive factors for survival outcomes of oligometastatic prostate cancer patients treated with metastases-directed therapy: a recursive partitioning-based analysis.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2019, v. 145, n. 10, p. 2469, doi. 10.1007/s00432-019-03007-w
- By:
- Publication type:
- Article
Patient-derived, three-dimensional spheroid cultures provide a versatile translational model for the study of organ-confined prostate cancer.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2019, v. 145, n. 3, p. 551, doi. 10.1007/s00432-018-2803-5
- By:
- Publication type:
- Article
Risk factors for unplanned discontinuation of scheduled treatment in elderly patients with castration-resistant prostate cancer: results of the IBuTu study.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2018, v. 144, n. 3, p. 571, doi. 10.1007/s00432-017-2577-1
- By:
- Publication type:
- Article
The value of baseline 18F-sodium fluoride and 18F-choline PET activity for identifying responders to radium-223 treatment in castration-resistant prostate cancer bone metastases.
- Published in:
- European Radiology, 2024, v. 34, n. 2, p. 1146, doi. 10.1007/s00330-023-10172-7
- By:
- Publication type:
- Article
The prevalence and locations of bone metastases using whole-body MRI in treatment-naïve intermediate- and high-risk prostate cancer.
- Published in:
- 2021
- By:
- Publication type:
- journal article
MRI-derived PRECISE scores for predicting pathologically-confirmed radiological progression in prostate cancer patients on active surveillance.
- Published in:
- European Radiology, 2021, v. 31, n. 5, p. 2696, doi. 10.1007/s00330-020-07336-0
- By:
- Publication type:
- Article
Multiparametric magnetic resonance imaging can exclude prostate cancer progression in patients on active surveillance: a retrospective cohort study.
- Published in:
- European Radiology, 2020, v. 30, n. 11, p. 6042, doi. 10.1007/s00330-020-06997-1
- By:
- Publication type:
- Article
Shortening the acquisition time of whole-body MRI: 3D T1 gradient echo Dixon vs fast spin echo for metastatic screening in prostate cancer.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Shear-wave elastography: role in clinically significant prostate cancer with false-negative magnetic resonance imaging.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Efficacy and Safety of Actinium-225 Prostate-Specific Membrane Antigen Radioligand Therapy in Metastatic Prostate Cancer: A Systematic Review and Metanalysis.
- Published in:
- Medical Principles & Practice, 2023, v. 32, n. 3, p. 178, doi. 10.1159/000531246
- By:
- Publication type:
- Article
Photoactivation of pheophorbide-a utilizing 670 nm LEDs elicits cancer suppressive effects in androgen-independent prostate cancer cellular models.
- Published in:
- Journal of Pharmacy & Pharmacology, 2023, v. 75, n. 12, p. 1544, doi. 10.1093/jpp/rgad083
- By:
- Publication type:
- Article
Effect of Dexamethasone on Abiraterone Pharmacokinetics in Mice: Determined by LC/MS Analysis.
- Published in:
- Medicines, 2023, v. 10, n. 3, p. 21, doi. 10.3390/medicines10030021
- By:
- Publication type:
- Article
Enzalutamide in Metastatic Castration-Resistant Prostate Cancer, Real-World Data.
- Published in:
- Eurasian Journal of Medical Investigation, 2023, v. 7, n. 1, p. 1, doi. 10.14744/ejmi.2022.32466
- By:
- Publication type:
- Article
Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421).
- Published in:
- Journal of Patient-Reported Outcomes, 2018, v. 2, n. 1, p. N.PAG, doi. 10.1186/s41687-018-0054-5
- By:
- Publication type:
- Article
[<sup>177</sup>Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP).
- Published in:
- Internal Medicine Research Review, 2021, n. 70, p. 4
- By:
- Publication type:
- Article
Disability weights for castration-resistant prostate cancer: an empirical investigation.
- Published in:
- Global & Regional Health Technology Assessment, 2022, v. 9, n. 1, p. 146, doi. 10.33393/grhta.2022.2431
- By:
- Publication type:
- Article
Talzenna Receives New Indication, With Enzalutamide, for Metastatic Castration-Resistant Prostate Cancer With HRR Gene Mutation.
- Published in:
- Value-Based Cancer Care, 2023, v. 14, n. 4, p. 14
- Publication type:
- Article
NEW COMBINATION.
- Published in:
- Value-Based Cancer Care, 2023, v. 14, n. 5, p. 13
- Publication type:
- Article
Darolutamide plus ADT and Docetaxel Improves Survival in Men with Metastatic Hormone- Sensitive Prostate Cancer.
- Published in:
- Value-Based Cancer Care, 2022, v. 13, n. 3, p. 1
- By:
- Publication type:
- Article
Continuous Enzalutamide Reduces Risk for Progression in Patients with Metastatic Castration-Resistant Prostate Cancer.
- Published in:
- Value-Based Cancer Care, 2022, v. 13, n. 2, p. 1
- By:
- Publication type:
- Article
Lynparza Receives FDA Approval for Adjuvant Treatment of High-Risk Early Breast Cancer.
- Published in:
- Value-Based Cancer Care, 2022, v. 13, n. 2, p. 12
- Publication type:
- Article
177Lu-PSMA-617 Prolongs Survival in Patients with Metastatic Castration-Resistant Prostate Cancer.
- Published in:
- Value-Based Cancer Care, 2021, v. 12, n. 4, p. 10
- By:
- Publication type:
- Article
FDA NEWS.
- Published in:
- Value-Based Cancer Care, 2021, v. 12, n. 2, p. 7
- Publication type:
- Article
Opdivo plus Yervoy First Immunotherapy Approved for Unresectable Malignant Pleural Mesothelioma.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 6, p. 24
- Publication type:
- Article
Olaparib a New Option for Men with Metastatic Prostate Cancer and BRCA Mutation.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 5, p. 29
- By:
- Publication type:
- Article
Cabozantinib plus Atezolizumab Combination Shows Meaningful Activity in Metastatic Prostate Cancer.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 4, p. 28
- By:
- Publication type:
- Article
Oral Relugolix Equals Standard ADT, Slashes Cardiac Events in Patients with Advanced Prostate Cancer.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 4, p. 1
- By:
- Publication type:
- Article
FDA Approves Nivolumab plus Ipilimumab for Hepatocellular Carcinoma.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 2, p. 14
- Publication type:
- Article